Молекулярні механізми негативного впливу метаболічного синдрому на ризик виникнення та прогноз перебігу раку молочної залози у жінок у постменопаузі
DOI:
https://doi.org/10.24026/1818-1384.3(40).2012.83259Ключові слова:
breast cancer, metabolic syndrome, breast cancer risk and prognosis, the molecular mechanismsАнотація
Breast cancer and metabolic syndrome remains one of the most urgent problems of modern medicine worldwide. In this review, highlights the molecular pathways that underlie the negative impact of metabolic syndrome on the risk and prognosis of breast cancer. A better understanding of these pathways will help to optimize prevention and treatment of breast cancer in patients with metabolic syndrome.
Посилання
Бернштейн Л. М. Онкоэндокринология: Традиции, современность и перспективы. – СПб.: Наука, 2004. – 343 с.
Перцева М. Н. Вклад эволюционной эндокринологии в изучение структуры и механизмов действия инсулина // Ж. эвол. биохим. и физиол. – 1999. – №35. – С. 175-186.
Щепотіт І. Б., Зотов О. С., Любота Р. В., Любота І. І. Клінічні та лабораторні показники синдрому інсулінорезистентності як фактори прогнозу перебігу раку молочної залози // Науковий вісник Національного медичного університету ім. О. О. Богомольця. – 2007. – №2. – С. 168-172.
Agnoli C., Berrino F., Abagnato C.A., Muti P., Panico S., Crosignani P., Krogh V. Metabolic syndrome and postmenopausal breast cancer in the ORDET cohort: a nested case-control study // Nutr. Metab. Cardiovasc. Dis. – 2010. – Vol. 20, №1. – P. 41-48.
Ando S., Catalano S. The multifactorial role of leptin in driving the breast cancer microenvironment. Nature Reviews Endocrinology. – 2012. – Vol. 8, №5. – P. 263-275.
Bachelot T., Ray-Coquard I., Menetrier-Caux C., Rastkha M., Duc A., Blay J.Y. Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients // British Journal of Cancer. – 2003. – №88. – P. 1721-1726.
Balkwill F. TNF-α in promotion and progression of cancer // Cancer Metastasis Rev. – 2006. – №25. – P. 409-416.
Bjorbaek C., Uotani S., da Silva B. et al. Divergent signaling capacities of the long and short isoforms of the leptin receptor // J. Biol. Chem. – 1997. – Vol. 51, №272. – P. 32686-32695.
Brakenhielm E., Veitonmaki N., Cao R. et al. Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis // Proc. Natl. Acad. Sci. USA. – 2004. – Vol. 101. – P. 2476-2481.
Bulun S., Simpson E. Breast cancer and expression of aromatase in breast adipose tissue // Trends Endocrinol. Metab. – 1994. – №5. – P. 113-120.
Catalano M.G., Frairia R., Boccuzzi G., Fortunati N. Sex hormoneinding globulin antagonizes the anti-apoptotic effect of estradiol in breast cancer cells // Molecular & Cellular Endocrinology. – 2005. – Vol. 230, №1. – P. 31-37.
Carswell E.A., Old L.J, Kassel R.L. et al. An endotoxin-induced serum factor that causes necrosis of tumors // Proc. Natl. Acad. Sci. USA. – 1975. – Vol. 72. – P. 3666-3670.
Clarke R.B., Howell A., Anderson E. Type I insulin-like growth factor receptor gene expression in normal human breast tissue treated with oestrogen and progesterone // British Journal of Cancer. – 1997 – Vol. 75, №4. – P. 251-257.
Chen G., Goeddel D.V. TNF-R1 signaling: a beautiful pathway // Science. – 2002. – Vol. 296. – P. 741-751.
Davies F.E., Rollinson S.J., Rawstron A.C. et al. High-producer haplotypes of tumor necrosis factor and lymphotoxin are associated with an increased risk of myeloma and have an improved progression-free survival after treatment // J. Clin. Oncol. – 2000. – Vol. 18, №4. – P. 2843-2851.
Dieudonne M.N., Machinal-Quelin F., Serazin-Leroy V., Leneveu M.C., Pecquery R. Giudicelli Y. Leptin mediates a proliferative response in human MCF7 breast cancer cells // Biochemical & Biophysical Research Communications. – 2002. – Vol. 293, №1. – P. 622-628.
DuBois R.N. Aspirin and breast cancer prevention: the estrogen connection // JAMA. – 2004. – Vol. 291, №20. – P. 2488-2489.
Folsom A.R., Kaye S.A., Prineas R.J., Potter J.D., Gapstur S.M., Wallace R.B. Increased incidence of carcinoma of the breast associated with abdominal adiposity in postmenopausal women // Am. J. Epidemiol. – 1990. – Vol. 131, №5. – P. 794-803.
Fortunati N., Fissore F., Fazzari A., Becchis M., Comba A., Catalano M.G., Berta L., Frairia R. Sex steroid binding protein exerts a negative control on estradiol action in MCF-7 cells (human breast cancer) through cyclic adenosine 30,50-monophosphate and protein kinase A // Endocrinology. – 1996. – Vol. 137, №29. – P. 686-692.
Fortunati N., Fissore F., Fazzari A., Piovano F., Catalano M.G., Becchis M., Berta L., Frairia R. Estradiol induction of cAMP in breast cancer cells is mediated by foetal calf serum (FCS) and sex hormone-binding globulin (SHBG) // Journal of Steroid Biochemistry & Molecular Biology. – 1999. – Vol. 70, №2. – P. 73-80.
Furberg A.S., Veierod M.B., Wilsgaard T., Bernstein L., Thune I. Serum high-density lipoprotein cholesterol, metabolic profile, and breast cancer risk // J. Natl. Cancer Inst. – 2004. – Vol. 96, №5. – P. 1152-1160.
Garcia Rodriguez L.A., Gonzalez-Perez A. Risk of breast cancer among users of aspirin and other anti-inflammatory drugs // Br. J. Cancer. – 2004. – Vol. 91, №3. – P. 525-529.
Giovannucci E., Harlan D.M., Archer M.C., Bergenstal R.M., Gapstur S.M., Habel L.A., Pollak M., Regensteiner J.G., Yee D. Diabetes and cancer: a consensus report // CA Cancer J. Clin. – 2010. – Vol. 60, №4. – P. 207-221.
Goodwin P.J., Ennis M., Pritchard K.I., Trudeau M.E., Koo J., Madarnas Y., Hartwick W., Hoffman B., Hood N. Fasting insulin and outcome in earlystage breast cancer: results of a prospective cohort study // Journal of Clinical Oncology. – 2002. – Vol. 20, №1. – P. 42-51.
Goodwin P.J., Stambolic V., Lemieux J. et al. Evaluation of metformin in early breast cancer: a modification of the traditional paradigm for clinical testing of anti-cancer agents // Breast Cancer Res. Treat. – 2011. – Vol. 126, №1. – P. 215-220.
Govindarajan B., Klafter R., Miller M.S. et al. Reactive oxygen-induced carcinogenesis causes hypermethylation of p16 (Ink4a) and activation of MAP kinase // Mol. Med. – 2002. – Vol. 8, №1. – P. 1-8.
Grimberg A., Cohen P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis // J. Cell Physiol. – 2000. – Vol. 183, 1 . – P. 1-9.
Godden J., Leake R., Kerr D.J. The response of breast cancer cells to steroid and peptide growth factors // Anticancer Research . – 1992. – Vol. 12, №5. – P. 1683-1688.
Grodin J.M., Siiteri P.K., MacDonald P.C. Source of estrogen production in postmenopausal women // Journal of Clinical Endocrinology & Meta-bolism. – 1973. – Vol. 36, №2. – P. 207-214.
Hahn W.C., Weinberg R.A. Rules for making human tumor cells // N. Engl. J. Med. – 2002. – Vol. 347, №20. – P. 1593-1603.
Helle S.I., Holly J.M., Tally M. et al. Influence of treatment with tamoxifen and change in tumor burden on the IGF-system in breast cancer patients // Int. J. Cancer. – 1996. – Vol. 69, №4 – P. 335-339.
Hu X., Juneja S.C., Maihle N.J., Cleary M.P. Leptin – a growth factor in normal and malignant breast cells and for normal mammary gland development // Journal of the National Cancer Institute. – 2002. – Vol. 94, №22. – P. 1704-1711.
Igata M., Motoshima H., Tsuruzoe K. et al. Adenosine monophosphate-activated protein kinase suppresses vascular smooth muscle cell proliferation through the inhibition of cell cycle progression // Circ. Res. – 2005. – Vol. 97, №7. – P. 837-844.
Il'yasova D., Colbert L.H., Harris T.B. et al. Circulating levels of inflammatory markers and cancer risk in the health aging and body composition cohort // Cancer Epidemiol. Biomarkers Prev. – 2005. – Vol. 14, №10. – P. 2413-2418.
International Diabetes Federation Epidemiology Task Force Consensus Group. The IDF consensus world wide definition of the metabolic syndrome. International Diabetes Federation. Brussels: 2005. (Available at: www.idf.org/webdata/docs/IDF Metasyndrome definition.pdf).
Ishikawa M., Kitayama J., Nagawa H. Enhanced expression of leptin and leptin receptor (OB-R) in human breast cancer // Clin. Cancer Res. – 2004. – Vol. 10, №13. – P. 4325-4331.
Iyengar P., Combs T.P., Shah S.J., Gouon-Evans V., Pollard J.W., Albanese C., Flanagan L., Tenniswood M.P., Guha C., Lisanti M.P. et al. // Adipocyte-secreted factors synergistically promote mammary tumorigenesis through induction of antiapoptotic transcriptional programs and proto-oncogene stabilization // Oncogene. – 2003. – Vol. 22 №41. – P. 6408-6423.
Irwin M.L., McTiernan A., Bernstein L., Gilliland F.D., Baumgartner R., Baumgartner K., Ballard-Barbash R. Relationship of obesity and physical activity with C-peptide, leptin, and insulin-like growth factors in breast cancer survivors // Cancer Epidemiol. Biomarkers Prev. – 2005. – Vol. 14, №12. – P. 2881-2888.
Jalving M., Gietema J.A., Lefrandt J.D. et al. Metformin: taking away the candy for cancer? // Eur. J. Cancer. – 2010. – Vol. 46, №13. – P. 2369-2380.
Jarde T., Caldefie-Chezet F., Damez M. et al. Leptin and leptin receptor involvement in cancer development: a study on human primary breast carcinoma // Oncol. Rep. – 2008. – Vol. 19, №4. – P. 905-911.
Josefson D. High insulin levels linked to deaths from breast cancer // BMJ. – 2000. – Vol. 320, Issue 7248. – P. 1496.
Kishimoto T. Interleukin-6: from basic science to medicine – 40 years in immunology // Ann. Rev. Immunol. – 2005. – Vol. 23, №1. – P. 1-21.
Kulbe H., Thompson R., Wilson J.L. et al. The inflammatory cytokine tumor necrosis factor- generates an autocrine tumor-promoting network in epithelial ovarian cancer cells // Cancer Res. – 2007. – Vol. 67, №2. – P. 585-592.
Laud K., Gourdou I., Pessemesse L., Peyrat J.P., Djiane J. Identification of leptin receptors in human breast cancer: functional activity in the T47-D breast cancer cell line // Molecular & Cellular Endocrinology. – 2002. – Vol. 188, №1-2. – P. 219-226.
Lee P.D., Giudice L.C., Conover C.A., Powell D.R. Insulin-like growth factor binding protein-1: recent findings and new directions. // Proc. Soc. Exp. Biol. Med. – 1997 – Vol. 216, № 3. – P. 319-357.
Lipscombe L.L., Goodwin P.J., Zinman B., McLaughlin J.R., Hux J.E. Diabetes mellitus and breast cancer: a retrospective population-based cohort study // Breast Cancer Res. Treat. – 2006. – Vol. 98, №3. – P. 349-356.
Lipscombe L.L., Goodwin P.J., Zinman B., McLaughlin J.R., Hux J.E. The impact of diabetes on survival following breast cancer // Breast Cancer Res. Treat. – 2008. – Vol. 109, №2. – P. 389-395.
Maeso Fortuny M.C., Brito Diaz B., Cabrera de Leon A. Leptin, estrogens and cancer // Mini Rev. Med. Chem. – 2006. – Vol. 6, №8. – P. 897-907.
Manabe Y., Toda S., Miyazaki K., Sugihara H. Mature adipocytes, but not preadipocytes, promote the growth of breast carcinoma cells in collagen gel matrix culture through cancer-stromal cell interactions // Journal of Pathology. – 2003. – Vol. 201, №2. – P. 221-228.
Mantzoros C., Petridou E., Dessypris N. et al. Adiponectin and breast cancer risk // J. Clin. Endocrinol. Metab. – 2004. – Vol. 89, №3. – P. 1102-1107.
McTiernan A., Irwin M., Von Gruenigen V. Weight, Physical Activity, Diet, and Prognosis in Breast and Gynecologic Cancers // Journal of Clinical Oncology. – 2010. – Vol. 28, №26. – P. 4074-4080.
McTiernan A., Rajan K.B., Tworoger S.S., Irwin M., Bernstein L., Baumgartner R., Gilliland F., Stanczyk F.Z., Yasui Y., Ballard-Barbash R. Adiposity and sex hormones in postmenopausal breast cancer survivors // Journal of Clinical Oncology. – 2003. – Vol. 21, №10. – P. 1961-1966.
Michels K.B., Solomon C.G., Hu F.B., Rosner B.A., Hankinson S.E., Colditz G.A., Manson J.E. Type 2 diabetes and subsequent incidence of breast cancer in the Nurses' Health Study // Diabetes Care. – 2003. – Vol. 26, №6. – P. 1752-1758.
Mink P.J., Shahar E., Rosamond W.D., Alberg A.J., Folsom A.R. Serum insulin and glucose levels and breast cancer incidence: the atherosclerosis risk in communities study // American Journal of Epidemiology. – 2002. – Vol. 156, №4. – P. 349-352.
Miyoshi Y., Funahashi T., Kihara S., Taguchi T., Tamaki Y., Matsuzawa Y., Noguchi S. Association of serum adiponectin levels with breast cancer risk // Clinical Cancer Research. – 2003. – Vol. 9, №15. – P. 5699-5704.
Morimot, L.M., White E., Chen Z., Chlebowski R.T., Hays J., Kuller L., Lopez A.M., Manson J., Margolis K.L., Muti P.C. et al. Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States) // Cancer Causes Contr. – 2002. – Vol. 13, №5. – P. 741-751.
Moschos S.J., Mantzoros C.S. The role of the IGF system in cancer: from basic to clinical studies and clinical applications // Oncology. – 2002. – Vol. 63, №4. – P. 317-332.
Muti P., Quattrin T., Grant B. J., Krogh V., Micheli A., Schunemann H.J., Ram M., Freudenheim J.L., Sieri S., Trevisan M., Berrino F. Fasting glucose is a risk factor for breast cancer: a prospective study // Cancer Epidemiol. Biomarkers Prev. – 2002. – Vol. 11, №3. – P. 1361-1368.
Okumura M., Yamamoto M., Sakuma H., Kojima T., Maruyama T., Jamali M., Cooper D.R., Yasuda K. Leptin and high glucose stimulate cell proliferation in MCF-7 human breast cancer cells: reciprocal involvement of PKC-alpha and PPAR expression // Biochimica et Biophysica Acta. – 2002. – Vol. 1592, №2. – P. 107-116.
Otvos L.J., Kovalszky I., Scolaro L. et al. Peptidebased leptin receptor antagonists for cancer treatment and appetite regulation // Peptide Science. – 2011. – Vol. 96, №2. – P. 117-125.
Ouchi N., Kihara S., Funahashi T. et al. Reciprocal association of C-reactive protein with adiponectin in blood stream and adipose tissue // Circulation. – 2003. – Vol. 107, №5. – P. 671-674.
Ouedraogo R., Wu X., Xu S.Q. et al. Adiponectin suppression of high-glucose-induced reactive oxygen species in vascular endothelial cells: evidence for involvement of a cAMP signaling pathway // Diabetes. – 2006. – Vol. 55, №6. – P. 1840-1846.
Pasanisi P., Berrino F., De Petris M., Venturelli E., Mastroianni A., Panico S. Metabolic syndrome as a prognostic factor for breast cancer recurrences // Int. J. Cancer. – 2006. – Vol. 119, №1. – P. 236-238.
Peeters P.H., van Noord P.A., Hoes A.W., Fracheboud J., Gimbrere C.H., Grobbee D.E. Hypertension and breast cancer risk in a 19-year follow-up study (the DOM cohort). Diagnostic investigation into mammarian cancer // J. Hypertens. – 2000. – Vol. 18, №3. – P. 249-254.
Peeters P.H., van Noord P.A., Hoes A.W., Grobbee D.E. Hypertension, antihypertensive drugs, and mortality from cancer among women // J. Hypertens. – 1998. – Vol. 16, №7. – P. 941-947.
Pollak M.N., Huynh H.T., Lefebvre S.P. Tamoxifen reduces serum insulin-like growth factor I (IGF-I) // Breast Cancer Res. Treat. – 1992. – Vol. 22, №1. – P. 91-100.
Pugeat M., Crave J.C., Elmidani M., Nicolas M.H., Garoscio-Cholet M., Lejeune H., Dechaud H., Tourniaire J. Pathophysiology of sex hormone binding globulin (SHBG): relation to insulin // Journal of Steroid Biochemistry & Molecular Biology. – 1991. – Vol. 40, №6. – P. 841-849.
Purohit A., Newman S.P., Reed M.J. The role of cytokines in regulating estrogen synthesis: implications for the etiology of breast cancer // Breast Cancer Research. – 2002. – Vol. 4, №2. – P. 65-69.
Resnicoff M., Baserga R. The role of insulin-like growth factor-I receptor in transformation and apoptosis // Ann. NY Acad. Sci. – 1998. – Vol. 842. – P. 76-81.
Richardson L.C., Pollack L.A. Therapy insight: influence of type 2 diabetes on the development, treatment and outcomes of cancer // Nat. Clin. Pract. Oncol. – 2005. – Vol. 2, №1. – P. 48-53.
Sachdev D., Yee D. The IGF system and breast cancer // Endocrine-Related Cancer. – 2001. – Vol. 8, №3. – P. 197-209.
Schafer Z.T., Brugge J.S. IL-6 involvement in epithelial cancers // J. Clin. Invest. – 2007. – Vol. 117, №12. – P. 3660-3663.
Suganuma M., Okabe S., Marino M.W. et al. Essential role of tumor necrosis factor (TNF-α) in tumor promotion as revealed by TNF-α-deficient mice // Cancer Res. -1999. – Vol. 59, №22. – P. 4516-4518.
Terry M.B., Gammon M.D., Zhang F.F. et al. Association of frequency and duration of aspirin use and hormone receptor status with breast cancer risk // JAMA. – 2004. – Vol. 291, №20. – P. 2433-2440.
van Landeghem A.A., Poortman J., Nabuurs M., Thijssen J.H. Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue // Cancer Research. – 1985. – Vol. 45, №6. – P. 2900-2906.
Wolf I., Sadetzki S., Catane R. et al. Diabetes mellitus and breast cancer // Lancet Oncol. – 2005. – Vol. 6, №2. – P. 103-111.
"World Cancer Report". International Agency for Research on Cancer. 2008. Retrieved 2011-02-26.
Xia X.H., Gu J.C., Bai Q.Y. et al. Overexpression of leptin and leptin receptors in breast cancer positively correlates with clinicopathological features // Chin. Med. J. (Engl.). – 2009. – Vol. 122, №24. – P. 3078-3081.
Yamauchi T., Kamon J., Ito Y., Tsuchida A., Yokomizo T., Kita S., Sugiyama T., Miyagishi M., Hara K., Tsunoda M. et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects // Nature. – 2003. – Vol. 423, №6941. – P. 762-769.
Yamauchi T., Kamon J., Waki H. et al. The fatderived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity // Nat. Med. – 2001. – Vol. 7, №8. – P. 941-946.
Zeleniuch-Jacquotte A., Shore R.E., Koenig K.L., Akhmedkhanov A., Afanasyeva Y., Kato I., Kim M.Y., Rinaldi S., Kaaks R., Toniolo P. Postmenopausal levels of oestrogen, androgen, and SHBG and breast cancer: long-term results of a prospective study // British Journal of Cancer. – 2004. – Vol. 90, №1. – P. 153-159.
Zhang Y., Coogan P.F., Palmer J.R. et al. Use of nonsteroidal antinflammatory drugs and risk of breast cancer: the Case-Control Surveillance Study revisited // Am. J. Epidemiol. – 2005. – Vol. 162, №2. – P. 165-170.
Zong C.S., Zeng L., Jiang Y., Sadowski H.B., Wang L.H. Stat3 plays an important role in oncogenic Ros- and insulin-like growth factor I receptor-induced anchorage-independent growth // J. Biol. Chem. – 1998. – Vol. 273, №43. – P. 28065-28072.
##submission.downloads##
Опубліковано
Номер
Розділ
Ліцензія
Авторське право (c) 2017 Клінічна ендокринологія та ендокринна хірургія
Ця робота ліцензується відповідно до Creative Commons Attribution-NonCommercial 4.0 International License.
